ABBOTT LABORATORIES
ABTNYSEHealthcare · Pharmaceutical Preparations · IL · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $44.33B | $41.95B | $40.11B | $43.65B | $43.08B | $34.61B |
| Operating income | $8.05B | $6.83B | $6.48B | $8.36B | $8.43B | $5.36B |
| Net income | $6.52B | $13.40B | $5.72B | $6.93B | $7.07B | $4.50B |
| Total assets | $86.71B | $81.41B | $73.21B | $74.44B | $75.20B | $72.55B |
| Total liabilities | — | — | — | — | — | — |
| Equity | $52.13B | $47.66B | $38.60B | $36.69B | $35.80B | $32.78B |
| EPS (diluted) | $3.72 | $7.64 | $3.26 | $3.91 | $3.94 | $2.50 |
| Shares out. | 1.73B | 1.74B | 1.74B | 1.76B | 1.77B | 1.76B |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 18.2%
- Net margin
- 14.7%
- Return on equity
- 12.5%
- Return on assets
- 7.5%
- Return on capital (ROCE)
- 11.5%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $30.06
- Revenue growth (YoY)
- 5.7%
- Net income growth (YoY)
- −51.3%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −3.5%clean
- Piotroski F-Score
- 5/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 4 good- Operating margin is positive
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Capital Management LlcPassive (13G)Apr 29, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 23.2M | 1.7 | +3.0% |
| Apr 30, 2026 | 22.5M | 1.5 | +3.6% |
| Apr 15, 2026 | 21.7M | 2.3 | -8.7% |
| Mar 31, 2026 | 23.8M | 1.6 | +19.4% |
| Mar 13, 2026 | 20.0M | 2.3 | +9.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer change · Amended charter or bylaws · Shareholder voteApr 27, 2026
- Other material eventApr 17, 2026
- Results of operationsApr 16, 2026
- Other material eventMar 23, 2026
- Entered a material agreement · New financial obligationMar 9, 2026
- Entered a material agreementFeb 26, 2026
- Amended charter or bylawsFeb 20, 2026
- Results of operationsJan 22, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Corporate family
Spin-offs from ABBOTT LABORATORIES (2)
- AbbVie Inc.ABBVcompletedDec 31, 2012details
- HOSPIRA INCcompletedApr 29, 2004details
From the spin-off filings we track. Follow a company to walk its own history.